Harmony Biosciences Net Income Over Time
| HRMY Stock | USD 36.01 0.16 0.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Harmony Biosciences Performance and Harmony Biosciences Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. Market participants price Harmony higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Harmony Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.101 | Earnings Share 3.17 | Revenue Per Share | Quarterly Revenue Growth 0.287 | Return On Assets |
Harmony Biosciences's market price often diverges from its book value, the accounting figure shown on Harmony's balance sheet. Smart investors calculate Harmony Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Harmony Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Harmony Biosciences and related stocks such as Vera Therapeutics, Aurinia Pharmaceuticals, and Celldex Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| AUPH | (2.2 M) | (2.4 M) | (9.7 M) | (2.5 M) | (16.6 M) | (18.6 M) | (23.3 M) | (70.8 M) | (64.1 M) | (88.4 M) | (102.7 M) | (181 M) | (108.2 M) | (78 M) | 5.8 M | 5.2 M | 5.4 M |
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
| MNKD | (24.7 M) | (160.8 M) | (169.4 M) | (191.5 M) | (198.4 M) | (368.4 M) | 125.7 M | (117.3 M) | (87 M) | (51.9 M) | (57.2 M) | (80.9 M) | (87.4 M) | (11.9 M) | 27.6 M | 31.7 M | 33.3 M |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| BHVN | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (118.7 M) | (213.8 M) | (570.3 M) | (408.2 M) | (846.4 M) | (761.8 M) | (723.7 M) |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| IMCR | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (103.9 M) | (74.1 M) | (180 M) | (43.5 M) | (55.3 M) | (40.8 M) | (46.9 M) | (49.3 M) |
| SION | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (47.3 M) | (61.7 M) | (55.5 M) | (58.3 M) |
Harmony Biosciences and related stocks such as Vera Therapeutics, Aurinia Pharmaceuticals, and Celldex Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Harmony Biosciences financial statement analysis. It represents the amount of money remaining after all of Harmony Biosciences Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Harmony Biosciences Holdings | HRMY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 630 West Germantown |
| Exchange | NASDAQ Exchange |
USD 36.01
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.